The Proof of Government: What Medicare's First Ten Drugs Taught America About Power
Photo: Hamilton, A. L., Public domain, via Wikimedia Commons
In August 2024, the Biden administration announced the negotiated prices for the first ten prescription drugs under the Inflation Reduction Act — including Eliquis, Jardiance, and Januvia — with projected savings of roughly $6 billion in the first year alone, and an estimated $1.5 billion in out-of-pocket savings for beneficiaries, according to the Department of Health and Human Services. It was the first time in the nearly sixty-year history of Medicare that the program was allowed to ask a simple question: what if the largest purchaser of prescription drugs on earth negotiated like one?
The Most Radical Idea in America Is That Government Should Deliver
For progressives, this is the argument to make in every kitchen-table conversation for the next decade. The drug price negotiation provision is not a technocratic footnote to the IRA. It is a controlled experiment with a published result: when government uses its collective power on behalf of ordinary people, material conditions improve. Not hypothetically. Not in a model. In a CBO-scored, HHS-published, senior's-copay-reduced way.
The second round of negotiations — covering fifteen additional drugs, with prices taking effect in 2027 — was selected in early 2025, including Ozempic and other GLP-1 medications whose list prices have put them out of reach for millions of Americans with diabetes and obesity. The expansion of negotiation to more drugs over the coming years is where the real money is: CBO projected substantial federal savings as the negotiated universe grows.
The Counteroffensive
The pharmaceutical industry has not taken this lying down. PhRMA and member companies have pursued litigation challenging the constitutionality of the negotiation program — arguing, in essence, that the program's penalties for non-participation amount to compelled speech under the First Amendment. Courts have so far been unpersuaded in the early rounds, with federal judges dismissing several challenges for lack of standing, though appeals have continued.
The lobbying arm of the effort is quieter and arguably more dangerous. Pharma remains one of the largest lobbying forces in Washington, and industry allies in Congress have floated changes to slow or narrow the negotiation timeline. The strongest industry argument — that price controls will reduce investment in future innovation — deserves a real answer: the same companies charging Americans the highest drug prices in the developed world charge dramatically less in every other wealthy country, and they manage to innovate there too. America is not funding global R&D out of generosity; it is being charged a premium because it is the only market that let itself be charged one.
Who Benefits
Nearly 67 million people are enrolled in Medicare, and the negotiated prices apply to drugs taken by millions of them — blood thinners, diabetes medications, cancer therapies. The 2025 $2,000 out-of-pocket cap on Part D prescriptions, also from the IRA, is the difference between filling a prescription and choosing between medication and groceries. For seniors on fixed incomes, these are not statistics; they are monthly budgets.
The Electoral Lesson
Democrats have struggled to articulate a cost-of-living agenda that voters believe. This is the exception — a concrete, delivered, verifiable benefit with a Democratic signature. The task now is defense and expansion: protect negotiation from congressional rollback, extend it to more drugs sooner, and connect it to the broader case that public power can lower the price of living in America.
The verdict: government negotiation worked exactly as its proponents promised — and now the only question is whether the American people will insist on more of it.